Information Provided By:
Fly News Breaks for April 26, 2017
NUVA
Apr 26, 2017 | 05:59 EDT
Piper Jaffray analyst Matt O'Brien recommends buying NuVasive on today's post-earnings weakness. Management is being conservative with the Q2 revenue guidance and the fully year outlook was maintained, O'Brien tells investors in a research note. The story has "a lot to like" with the expanded sales force and new product introductions, the analyst contends. He raised his price target for the shares to $80 from $75 and reiterates an Overweight rating on NuVasive.
News For NUVA From the Last 2 Days
There are no results for your query NUVA